Please respond by suggesting additional patient factors that might have interfered with the pharmacokinetic and pharmacodynamic processes of the patients they described. In addition, suggest how the personalized plan of care might change if the age of the patient were different and/or if the patient had a comorbid condition, such as renal failure, heart failure, or liver failure. Initial post: Different patients present with varied clinical conditions with other underlying ailments. The existence of comorbidities affects both the choice of drug and the dosage prescribed for patient management. In my clinical practice, I interacted with a middle-aged male patient with end-stage renal disease (ESRD) in the cardiac unit of the intensive care unit (ICU). The patient had diabetes type 2 and was on metformin 1000mg taken twice daily orally. He was also hypertensive and was on 60mg Nifedipine taken twice once orally. When he reported to the facility, he had pulmonary edema, low blood pressure of 82/46mmHg, and had poor oxygen saturation levels that informed his admission to the ICU. This paper aims to discuss how the underlying condition affected the drug dosage and drug effect in this patient. Factors Affecting Pharmacokinetics The processes the drug undergoes after administration is referred to as the pharmacokinetic. These activities include drug absorption across membranes, distribution in the bloodstream, metabolism, and elimination (Keller & Hann, 2018). Drug distribution is subject to the available blood volume and cardiac output (Keller & Hann, 2018). In ESRD, there is water retention in the body which expands the blood volume; this reduces metformin’s volume of distribution and thus less bioavailability in the action site (Asif et al., 2019). Given the principal route of metformin elimination is renal; ESRD reduces glomerular filtration and tubular secretion of the drug thus leading to serum buildup of the drug and its metabolite in the body (Keller & Hann, 2018). Metformin effect is pronounced under these conditions. ESRD therefore requires dose adjustment for metformin. Factors Affecting Pharmacodynamics The drug’s pharmacodynamics is concerned with the drug’s actions in the human body. The drug actions are dependent on the number of available drug binding sites and also the drug’s serum concentration (Lea-Henry et al., 2018). In ESRD, serum metformin levels increase, and thus the direct metformin effects on glucose are exaggerated. The patient may therefore suffer from hypoglycemia. Further, interaction of the metformin and nifedipine can worsen the hypoglycemia (Thompson-Branch & Havranek, 2017). Moreover, Metformin’s effects on blocking gluconeogenesis may result in lactic acidosis which may complicate patient care (Asif et al., 2019). Nifedipine’s role in reducing blood pressure may result in low blood supply to the kidney resulting in ischemia and worsened renal disease (Lea-Henry et al., 2018).To prevent these pronounced drug effects, the physician should be able to understand different patient factors and their effect on pharmacotherapy. Individualized Therapy Plan To plan for pharmacotherapy in the patient, a drug dose adjustment is necessary. The dose can be upscaled or downscaled depending on the desired drug effect (Keller & Hann, 2018). In this patient, the metformin dose is reduced to 500mg twice daily. The nifedipine dosage is reduced to 20mg taken once daily because of the low blood pressure (Pugh et al., 2019). Adrenaline infusion of 4mcg/minute is given for cardiac inotropic support. Conclusion Drug action depends on the drug’s concentration in the body, delivery at the active sites, and the interaction of the drug with its receptors. If the serum drug concentration is reduced, a dose adjustment (increasing or decreasing the drug) is necessary. This limits the drug’s adverse effects or promotes the drug’s desired effects. References Asif, S., Bennett, J., & Marakkath, B. (2019). Metformin-associated Lactic Acidosis: An Unexpected Scenario. Cureus. https://doi.org/10.7759/cureus.4397 Keller, F., & Hann, A. (2018). Clinical Pharmacodynamics. Clinical Journal Of The American Society Of Nephrology, 13(9), 1413-1420. https://doi.org/10.2215/cjn.10960917 Lea-Henry, T., Carland, J., Stocker, S., Sevastos, J., & Roberts, D. (2018). Clinical Pharmacokinetics in Kidney Disease. Clinical Journal Of The American Society Of Nephrology, 13(7), 1085-1095. https://doi.org/10.2215/cjn.00340118 Pugh, D., Gallacher, P., & Dhaun, N. (2019). Management of Hypertension in Chronic Kidney Disease. Drugs, 79(4), 365-379. https://doi.org/10.1007/s40265-019-1064-1 Thompson-Branch, A., & Havranek, T. (2017). Neonatal Hypoglycemia. Pediatrics In Review, 38(4), 147-157. https://doi.org/10.1542/pir.2016-0063
The post Please respond by suggesting additional patient factors that might have interfer appeared first on homework handlers.